Clinical Trial: Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07775235) titled 'Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease' on April 23.

Brief Summary: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD). IIM-associated ILD carries poor prognosis. Particular subtypes of IIM such as anti-melanoma differentiation-associated protein 5 positive (anti-MDA5+) dermatomyositis with ILD are most commonly associated with rapidly progressive-interstitial lung disease (RP-ILD). RP-ILD is defined ...